SecBot SecBot
SECBOTREPLAY Home › Report › MIRM

MIRM · Mirum Pharmaceuticals reported Q2 2026 net product sales of $176.2M, a…

Mirum Pharmaceuticals, Inc. · 8-K filed Aug 5, 2026 at 16:02 ET

At the news

MIXEDIMPACT 6/10

8-K filed Aug 5, 2026 at 16:02 ET

Mirum Pharmaceuticals reported Q2 2026 net product sales of $176.2M, a 38% YoY increase, and raised full-year guidance to $680M-$700M. However, GAAP EPS was -$1.06, a significant miss vs the -$0.75 consensus, driven by heavy R&D and SG&A spending. The volixibat NDA submission was delayed to H1 2027 after the FDA recommended a Phase 3 study, a key pipeline setback. The strong commercial performance and raised guidance are offset by the earnings miss and the volixibat delay, resulting in a mixed outlook.

  • Q2 2026 net product sales of $176.2M, up 38% YoY from $127.8M.
  • Full-year 2026 net product sales guidance raised to $680M-$700M from $660M-$680M.
  • GAAP net loss per share of -$1.06 vs consensus of -$0.75 (a miss).
  • Volixibat NDA submission for PSC delayed to H1 2027 after FDA recommended a Phase 3 study.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access